| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Nintedanib |
| Brand | Vargatef® |
| Indication | Is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 02/01/2015 |
| Rapid review completed | 10/02/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 03/06/2015 |
| Preliminary review sent to Applicant | 25/03/2016 |
| NCPE assessment outcome | Reimbursement Not Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations February 2017.
